BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  SmithKline  Beecham  Biologicals  S.A.,  Belgium,  submitted  on  1  July  1999  to  the 
European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA),  an  application  to  obtain  a 
marketing  authorisation  in  accordance  with  the  Centralised  Procedure  for  the  medicinal  product 
Infanrix hexa (combined Diphtheria, Tetanus, acellular Pertussis, recombinant Hepatitis B, inactivated 
Poliovirus  and  Haemophilus  influenzae  type  b  vaccine)  falling  within  the  scope  of  Part  A  of  the 
Annex to Council Regulation No (EC) 2309/93. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur: 
Dr. Daniel Brasseur 
Co-Rapporteur: 
Dr. Manfred Haase 
Licensing status: 
The product was not licensed in any country inside or outside the EU at the time of submission of the 
application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 30 July 1999. 
The  Rapporteur’s  first  assessment  report  was  circulated  to  all  members  of  the  CPMP  on  11 
October 1999). 
The Co-Rapporteur’s first assessment report was circulated to all members of the CPMP on 6 
October 1999 In its meeting on 9-10 November 1999, the Biotechnology Working Party (BWP) 
discussed the draft list of questions on Part II of the dossier and endorsed the (Co)-Rapporteurs’ 
recommendation to the CPMP. A BWP report was prepared for adoption at the CPMP meeting 
on 16-18 November 1999. 
During  its  meeting  on  16-18  November  1999,  the  CPMP  agreed  on  the  consolidated  list  of 
questions to be sent to the applicant on 18 November 1999.  
The  applicant  submitted 
23 December 1999.  
the 
responses 
to 
the  consolidated 
list  of  questions  on 
The  Rapporteur  and  the  Co-Rapporteur  circulated  the  joint  response  assessment  report  on  the 
applicant’s  responses  to  the  consolidated  list  of  questions  to  all  CPMP  members  on 
22 February 2000.  
During its meeting on 7-8 March 2000, the Biotechnology Working Party (BWP) discussed the 
draft  list  of  outstanding  issues  on  Part  II  of  the  dossier  and  endorsed  the  (Co)-Rapporteur’s 
recommendation to the CPMP. A BWP report was prepared for adoption at the CPMP meeting 
on 14-16 March 2000. 
During its meeting on 14-16 March 2000, the CPMP agreed on a list of outstanding issues to be 
addressed by the company in writing (quality and safety issues) and during an oral explanation 
(safety issues) held on 24 May 2000. 
The applicant submitted the written responses to the outstanding issues on 3 May 2000. 
The  Rapporteur  circulated  a  further  assessment  report,  taking  into  account  the  company’s 
1/2 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
responses on the outstanding quality and safety issues, to all CPMP members on 12 May 2000. 
• 
• 
• 
• 
• 
An ad hoc expert group meeting on clinical issues was held on 22 May 2000 and a report from 
this meeting was circulated to all CPMP members on 23 May 2000.  
The  applicant  submitted  updated  information  relating  to  Part  II.V  of  the  dossier  to  all  CPMP 
Members on 15 June 2000. 
The Rapporteur’s assessment report on the supplementary information relating to Part II.V was 
circulated on 15 June 2000. 
During its meeting on 20-21 June 2000, the Biotechnology Working Party (BWP) discussed the 
Rapporteur’s  assessment  report  on  the  supplementary  information  relating  to  Part  II.V  of  the 
dossier and endorsed a recommendation to the CPMP. A BWP report was prepared for adoption 
at the CPMP meeting on 27-29 June 2000. 
During the  meeting on 27-29 June 2000, the  CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing  Authorisation  for  Infanrix  hexa  on  29  June  2000.  The  applicant  agreed  to  submit 
additional information regarding quality/clinical/safety data within the defined timeframe. 
2/2 
EMEA 2005 
 
 
 
 
 
 
 
